Bellevue Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bellevue Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27	Closed	-$21.1K	–	587
2026 Q1	$21.1K	Hold	27	–	–	0.01%	234
2025 Q4	$21K	Sell	27 -3	-10%	-$2.04K	0.01%	232
2025 Q3	$17K	Sell	30 -27	-47%	-$15.3K	0.01%	247
2025 Q2	$30K	Hold	57	–	–	0.01%	204
2025 Q1	$36.2K	Hold	57	–	–	0.02%	183
2024 Q4	$40.6K	Hold	57	–	–	0.02%	178
2024 Q3	$59.9K	Hold	57	–	–	0.03%	144
2024 Q2	$59.9K	Hold	57	–	–	0.03%	134
2024 Q1	$54.9K	Hold	57	–	–	0.03%	144
2023 Q4	$50.1K	Hold	57	–	–	0.04%	152
2023 Q3	$46.9K	Hold	57	–	–	0.03%	147
2023 Q2	$41K	Hold	57	–	–	0.03%	162
2023 Q1	$46.8K	Hold	57	–	–	0.03%	153
2022 Q4	$40.7K	Hold	57	–	–	0.03%	162
2022 Q3	$41K	Hold	57	–	–	0.03%	168
2022 Q2	$34K	Hold	57	–	–	0.02%	191
2022 Q1	$40K	Buy	57 +28	+97%	+$17.7K	0.02%	192
2021 Q4	$18K	Hold	29	–	–	0.01%	282
2021 Q3	$18K	Hold	29	–	–	0.01%	291
2021 Q2	$16K	Hold	29	–	–	0.01%	299
2021 Q1	$14K	Hold	29	–	–	0.01%	327
2020 Q4	$16K	Hold	29	–	–	0.01%	303
2020 Q3	$16K	Hold	29	–	–	0.01%	287
2020 Q2	$18K	Hold	29	–	–	0.02%	275
2020 Q1	$16K	Hold	29	–	–	0.02%	290
2019 Q4	$11K	Buy	+29	New	+$9.76K	0.01%	305

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bellevue Asset Management's REGN Position: Q2 2026 in Review

Bellevue Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 27 shares — an estimated $21.1K sold.

Bellevue Asset Management first reported a position in REGN in Q4 2019 and held it in 26 quarters. The position peaked at $59.9K in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Bellevue Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bellevue Asset Management sold 27 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $21.1K.
Bellevue Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 26 quarters.
Bellevue Asset Management's Regeneron Pharmaceuticals position peaked at $59.9K in Q3 2024.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bellevue Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.